6CM
INMB icon

683 Capital Management’s INmune Bio INMB Stock Holding History

683 Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,253
Closed -$217K – 196
2023
Q4 		$217K Buy
+19,253
New +$161K 0.02% 191

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

683 Capital Management's INMB Position: Q1 2024 in Review

683 Capital Management sold out of INmune Bio (INMB) in Q1 2024, closing a stake of 19,253 shares — an estimated $217K sold.

683 Capital Management first reported a position in INMB in Q4 2023 and held it in 1 quarter. The position peaked at $217K in Q4 2023. 52 funds tracked by Wall St. Rank hold INMB as of Q1 2024.

  • 683 Capital Management reported no remaining INmune Bio position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 19,253 INmune Bio shares in Q1 2024, an estimated $217K.
  • 683 Capital Management first reported a position in INmune Bio in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's INmune Bio position peaked at $217K in Q4 2023.
  • 52 funds tracked by Wall St. Rank held INmune Bio as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.